Two novel technologies that boost immune responses, including a synthetic toll-like receptor agonist for use as an adjuvant to vaccines , and a viral vector that targets immature dendritic cells
Start Trial Get Full Profile
There’s no risk. Start your trial today to see profiles of Immune Design plus 4842 other startups.
